Please login to the form below

Not currently logged in
Email:
Password:

R&D news in brief

Our weekly round-up of R&D news in brief

Long acting Risperdal shines in study
Patients with first episode psychosis experienced significant improvements in their symptoms and social functioning after treatment with Janssen-Cilag's Risperdal Consta, according to research presented at a schizophrenia workshop in Switzerland.

The study said the long-acting injectable drug was found to be effective and generally well tolerated in people experiencing a first episode of psychosis.

ìIt is vitally important that a person's first experience of antipsychotic treatment is positive, as this can have a lasting impact on the individual's attitude to taking medication long-term,î said lead investigator, Professor Robin Emsley from the University of Stellenbosch, South Africa.

Question mark over anti-clotting treatment
The practice of treating heart-attack victims as soon as possible with anti-clotting drugs doesn't benefit patients and increases the risk of subsequent heart attacks and strokes, a new study published in the Lancet suggests.

The practice, known as ìfacilitated angioplastyî is a popular course of action while patients await the procedure to unblock their arteries, known simply as angioplasty.

In a pooled analysis, involving more than 4,500 patients, the two kinds of drugs commonly used in facilitated angioplasty were studied: the so-called IIb/IIIa inhibitors, which prevent blood-clot formation, and the thrombolytics, which dissolve existing blood clots.

Using the drugs within hours of angioplasty led to more deaths, more subsequent heart attacks, more episodes of major bleeding and more strokes than angioplasty by itself, the study found.

30th September 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Complete Medical Communications (CMC)

CMC is a leading global agency dedicated to healthcare communications across the lifecycle. We combine scientific acumen, excellence in delivery...

Latest intelligence

Theresa Heggie
Alnylam’s big moment: bringing groundbreaking RNAi drugs to Europe
Theresa Heggie talks about the biotech’s 16-year path to market, and the promise of its ‘gene silencing’ medicines...
patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...

Infographics